{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:32:39Z","timestamp":1787967159572,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb Canada Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijcard.2026.134689","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:47:31Z","timestamp":1784962051000},"page":"134689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world effectiveness, response patterns and clinical implementation of Mavacamten in obstructive hypertrophic cardiomyopathy: Insights from the SWISS-MAVA cohort"],"prefix":"10.1016","volume":"462","author":[{"given":"Niccol\u00f2","family":"Maurizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina S.","family":"Vischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"St\u00e4mpfli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Monney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134689_bb0005","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134689_bb0010","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134689_bb0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134689_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center","volume":"86","author":"Desai","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2026.134689_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.042488","article-title":"Characteristics and outcomes of mavacamten use in 2440 patients with obstructive hypertrophic cardiomyopathy","volume":"14","author":"Mahana","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2026.134689_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034069","article-title":"Eighteen-month real-world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population","volume":"13","author":"Ramonfaur","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2026.134689_bb0035","article-title":"Mavacamten monotherapy in real-world patients with obstructive hypertrophic cardiomyopathy: evidence from COLLIGO-HCM","author":"Bilen","year":"2025","journal-title":"Circ Genom Precis Med."},{"issue":"3","key":"10.1016\/j.ijcard.2026.134689_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ehjci\/jeaf282","article-title":"Role of multi-modality cardiac imaging in the management of patients with hypertrophic cardiomyopathy in 2025. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC","volume":"27","author":"Cardim","year":"2026","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"1","key":"10.1016\/j.ijcard.2026.134689_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2025-003215","article-title":"Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Aman","year":"2025","journal-title":"Open Heart."},{"issue":"47","key":"10.1016\/j.ijcard.2026.134689_bb0055","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134689_bb0060","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","article-title":"Mavacamten: real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program","volume":"18","author":"Desai","year":"2025","journal-title":"Circ. Heart Fail."},{"issue":"Suppl C","key":"10.1016\/j.ijcard.2026.134689_bb0065","doi-asserted-by":"crossref","first-page":"C155","DOI":"10.1093\/eurheartjsupp\/suad042","article-title":"Stage-specific therapy for hypertrophic cardiomyopathy","volume":"25","author":"Argir\u00f2","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"issue":"1","key":"10.1016\/j.ijcard.2026.134689_bb0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","article-title":"Association of Obesity with Adverse Long-term Outcomes in hypertrophic cardiomyopathy","volume":"5","author":"Fumagalli","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"26","key":"10.1016\/j.ijcard.2026.134689_bb0075","article-title":"Incidence and outcomes of atrial fibrillation and systolic dysfunction in patients receiving Mavacamten for obstructive hypertrophic cardiomyopathy: a Multicenter study","volume":"S1071-9164","author":"Nguyen","year":"2026","journal-title":"J. Card. Fail."},{"issue":"9","key":"10.1016\/j.ijcard.2026.134689_bb0080","article-title":"Accelerated hypertension following mavacamten introduction in severe obstructive hypertrophic cardiomyopathy with hypertension: a case report","volume":"8","author":"Maurizi","year":"2024","journal-title":"Eur Heart J Case Rep."},{"issue":"37","key":"10.1016\/j.ijcard.2026.134689_bb0085","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1093\/eurheartj\/ehad429","article-title":"The European medicines agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients","volume":"44","author":"DeVries","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134689_bb0090","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.123.066916","article-title":"Pharmacogenetic influences over Mavacamten pharmacokinetics: considerations for the treatment of individuals with hypertrophic cardiomyopathy","volume":"149","author":"McGurk","year":"2024","journal-title":"Circulation"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326005395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326005395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:30:52Z","timestamp":1787675452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326005395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":17,"alternative-id":["S0167527326005395"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134689","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness, response patterns and clinical implementation of Mavacamten in obstructive hypertrophic cardiomyopathy: Insights from the SWISS-MAVA cohort","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"134689"}}